A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

Gastrointestinal Stromal Tumor(GIST) Clinical Trial

Official title:
A Multicenter Phase 2, Single-Arm Open-Label Study of DCC-2618 to Assess Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors Who Have Progressed On Prior Anticancer Therapies

Status Completed

Clinical Trial Summary

the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with imatinib. This study will enroll approximately 98 subjects in around 18 sites in China mainland, and all subjects will be receiving DCC-2618 or Sunitinib in equal chance as treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04633122
Study type	Interventional
Source	Zai Lab (Hong Kong), Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	November 25, 2020
Completion date	July 20, 2022

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05354388` - Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study
	Completed	`NCT03440515` - Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor	Phase 2